Bei Chunhua, Zhang Ying, Wei Riming, Zhu Xiaonian, Wang Zhigang, Zeng Wen, Chen Qiuyue, Tan Shengkui
Department of Epidemiology and Statistics, School of Public Health, Guilin Medical University.
Department of Hepatobiliary Surgery, The Affiliated Hospital of Guilin Medical University.
Onco Targets Ther. 2017 Nov 14;10:5439-5443. doi: 10.2147/OTT.S149786. eCollection 2017.
CMTM4 is the most conserved member of chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing (CMTM) family on chromosome 16q22.1, a locus that harbors a number of tumor-suppressor genes. In previous studies, CMTM4 was reported to be downregulated and exhibited tumor-suppressor activities by regulating cell growth and cell cycle in clear cell renal cell carcinoma. However, its roles in tumorigenesis of hepatocellular carcinoma (HCC) remain poorly studied. This study first investigated the expression of CMTM4 in HCC, and then examined the association between the expression of CMTM4 with the clinicopathological features and prognosis of HCC patients. It was found that CMTM4 was downregulated in HCC tissues, compared with matched adjacent nontumor tissues, as detected by immunohistochemistry. In addition, Kaplan-Meier survival analysis showed that the negative expression of CMTM4 was associated with decreased overall survival rates in patients with HCC. The results of this study suggest CMTM4 plays a role as a tumor suppressor in HCC and CMTM4 negative expression is a risk factor for poor prognosis of HCC.
CMTM4是16号染色体q22.1上趋化因子样因子(CKLF)样含MARVEL跨膜结构域(CMTM)家族中最保守的成员,该位点含有多个肿瘤抑制基因。在先前的研究中,据报道CMTM4在透明细胞肾细胞癌中表达下调,并通过调节细胞生长和细胞周期表现出肿瘤抑制活性。然而,其在肝细胞癌(HCC)发生发展中的作用仍研究较少。本研究首先调查了CMTM4在HCC中的表达情况,然后检测了CMTM4表达与HCC患者临床病理特征及预后之间的关联。免疫组织化学检测发现,与配对的癌旁非肿瘤组织相比,CMTM4在HCC组织中表达下调。此外,Kaplan-Meier生存分析表明,CMTM4的阴性表达与HCC患者总生存率降低有关。本研究结果提示,CMTM4在HCC中发挥肿瘤抑制作用,CMTM4阴性表达是HCC预后不良的危险因素。